Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 10 | 2022 | 180 | 4.760 |
Why?
|
| Head and Neck Neoplasms | 13 | 2023 | 135 | 4.310 |
Why?
|
| Parotid Neoplasms | 3 | 2021 | 13 | 2.260 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2022 | 23 | 2.130 |
Why?
|
| Tongue Neoplasms | 3 | 2021 | 16 | 2.110 |
Why?
|
| Laryngeal Neoplasms | 5 | 2023 | 29 | 2.050 |
Why?
|
| Robotic Surgical Procedures | 3 | 2020 | 18 | 1.880 |
Why?
|
| Adenocarcinoma | 2 | 2021 | 194 | 1.330 |
Why?
|
| Neck Dissection | 3 | 2021 | 17 | 1.310 |
Why?
|
| Retrospective Studies | 23 | 2023 | 3325 | 1.200 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2022 | 200 | 1.160 |
Why?
|
| Facial Nerve | 3 | 2021 | 13 | 1.130 |
Why?
|
| Parotid Gland | 3 | 2021 | 15 | 1.120 |
Why?
|
| Dissection | 3 | 2021 | 27 | 1.110 |
Why?
|
| Lymphatic Metastasis | 3 | 2021 | 87 | 1.070 |
Why?
|
| Salvage Therapy | 3 | 2023 | 36 | 1.010 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 37 | 0.940 |
Why?
|
| Postoperative Complications | 5 | 2020 | 957 | 0.930 |
Why?
|
| Drug Utilization | 2 | 2020 | 27 | 0.890 |
Why?
|
| Narcotics | 2 | 2020 | 34 | 0.870 |
Why?
|
| Analgesia | 2 | 2020 | 38 | 0.870 |
Why?
|
| Humans | 38 | 2023 | 29811 | 0.850 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 6 | 0.830 |
Why?
|
| Survival Rate | 8 | 2021 | 376 | 0.800 |
Why?
|
| Gloves, Surgical | 1 | 2021 | 7 | 0.760 |
Why?
|
| Neoplasm Seeding | 1 | 2021 | 8 | 0.750 |
Why?
|
| Male | 25 | 2023 | 15850 | 0.750 |
Why?
|
| Surgical Instruments | 1 | 2021 | 25 | 0.750 |
Why?
|
| Adenolymphoma | 1 | 2020 | 4 | 0.750 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2020 | 6 | 0.750 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2021 | 28 | 0.740 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2020 | 20 | 0.740 |
Why?
|
| Glottis | 1 | 2020 | 3 | 0.740 |
Why?
|
| Neoplasm Grading | 2 | 2021 | 53 | 0.730 |
Why?
|
| Middle Aged | 20 | 2021 | 9960 | 0.730 |
Why?
|
| Prescriptions | 1 | 2020 | 18 | 0.720 |
Why?
|
| Aged | 19 | 2023 | 9620 | 0.700 |
Why?
|
| Pain, Postoperative | 2 | 2020 | 318 | 0.690 |
Why?
|
| Chemoradiotherapy | 3 | 2023 | 69 | 0.690 |
Why?
|
| Human papillomavirus 16 | 1 | 2019 | 8 | 0.680 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2019 | 4 | 0.670 |
Why?
|
| Pharyngectomy | 1 | 2019 | 4 | 0.670 |
Why?
|
| Recovery of Function | 1 | 2020 | 291 | 0.660 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2019 | 51 | 0.660 |
Why?
|
| Female | 22 | 2021 | 16410 | 0.650 |
Why?
|
| Sarcoma | 1 | 2021 | 133 | 0.640 |
Why?
|
| Databases, Factual | 4 | 2021 | 331 | 0.520 |
Why?
|
| Tonsillar Neoplasms | 1 | 2014 | 3 | 0.480 |
Why?
|
| Meningeal Neoplasms | 1 | 2014 | 14 | 0.470 |
Why?
|
| Laryngectomy | 4 | 2023 | 17 | 0.470 |
Why?
|
| Dura Mater | 1 | 2014 | 21 | 0.460 |
Why?
|
| Adult | 13 | 2020 | 8741 | 0.460 |
Why?
|
| Teratoma | 1 | 2012 | 5 | 0.430 |
Why?
|
| Surgical Flaps | 1 | 2012 | 50 | 0.410 |
Why?
|
| Laryngeal Edema | 1 | 2011 | 2 | 0.400 |
Why?
|
| Angioedema | 1 | 2011 | 3 | 0.400 |
Why?
|
| Airway Obstruction | 1 | 2011 | 18 | 0.400 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 364 | 0.400 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 27 | 0.390 |
Why?
|
| Laryngeal Diseases | 1 | 2011 | 3 | 0.390 |
Why?
|
| Ear Diseases | 1 | 2011 | 3 | 0.390 |
Why?
|
| Nose Diseases | 1 | 2011 | 8 | 0.390 |
Why?
|
| Nose Neoplasms | 2 | 2022 | 34 | 0.380 |
Why?
|
| Gravitation | 1 | 2010 | 1 | 0.380 |
Why?
|
| Barotrauma | 1 | 2010 | 3 | 0.380 |
Why?
|
| Accidents | 1 | 2010 | 4 | 0.380 |
Why?
|
| Tympanic Membrane | 1 | 2010 | 4 | 0.380 |
Why?
|
| Ear Canal | 1 | 2010 | 4 | 0.380 |
Why?
|
| Head Movements | 1 | 2010 | 7 | 0.380 |
Why?
|
| Leisure Activities | 1 | 2010 | 12 | 0.380 |
Why?
|
| Tongue | 2 | 2021 | 8 | 0.380 |
Why?
|
| Acceleration | 1 | 2010 | 20 | 0.370 |
Why?
|
| Hypersensitivity | 1 | 2011 | 46 | 0.370 |
Why?
|
| Edema | 1 | 2010 | 39 | 0.370 |
Why?
|
| Prognosis | 3 | 2019 | 874 | 0.360 |
Why?
|
| Chylothorax | 1 | 2010 | 1 | 0.360 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 78 | 0.340 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 346 | 0.340 |
Why?
|
| Papillomaviridae | 2 | 2022 | 29 | 0.340 |
Why?
|
| United States | 6 | 2021 | 2344 | 0.340 |
Why?
|
| Cohort Studies | 4 | 2020 | 1952 | 0.330 |
Why?
|
| Young Adult | 6 | 2020 | 1966 | 0.330 |
Why?
|
| Betacoronavirus | 2 | 2020 | 75 | 0.330 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 191 | 0.320 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 86 | 0.310 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 89 | 0.310 |
Why?
|
| Lens Cortex, Crystalline | 1 | 2007 | 3 | 0.310 |
Why?
|
| Lens Nucleus, Crystalline | 1 | 2007 | 6 | 0.310 |
Why?
|
| Lens, Crystalline | 1 | 2007 | 32 | 0.300 |
Why?
|
| Adolescent | 4 | 2020 | 2332 | 0.280 |
Why?
|
| Treatment Outcome | 3 | 2020 | 3561 | 0.280 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2018 | 21 | 0.280 |
Why?
|
| Risk Assessment | 2 | 2019 | 683 | 0.280 |
Why?
|
| Margins of Excision | 2 | 2021 | 21 | 0.240 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2023 | 33 | 0.220 |
Why?
|
| Neck | 2 | 2023 | 34 | 0.220 |
Why?
|
| Otolaryngology | 2 | 2020 | 27 | 0.220 |
Why?
|
| Pilot Projects | 2 | 2022 | 403 | 0.220 |
Why?
|
| Free Tissue Flaps | 2 | 2019 | 13 | 0.210 |
Why?
|
| SEER Program | 2 | 2019 | 38 | 0.210 |
Why?
|
| Cell-Derived Microparticles | 1 | 2022 | 7 | 0.210 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 4930 | 0.200 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2022 | 53 | 0.200 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 379 | 0.200 |
Why?
|
| Age Factors | 3 | 2019 | 853 | 0.200 |
Why?
|
| Prospective Studies | 2 | 2021 | 1823 | 0.200 |
Why?
|
| Length of Stay | 2 | 2023 | 320 | 0.190 |
Why?
|
| Chondrosarcoma | 1 | 2021 | 33 | 0.190 |
Why?
|
| Cytological Techniques | 1 | 2021 | 14 | 0.190 |
Why?
|
| Pain Measurement | 2 | 2020 | 468 | 0.190 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2020 | 7 | 0.180 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2020 | 11 | 0.180 |
Why?
|
| Urban Health Services | 1 | 2020 | 13 | 0.180 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 24 | 0.180 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 34 | 0.180 |
Why?
|
| Risk Factors | 3 | 2021 | 2465 | 0.180 |
Why?
|
| Paraganglioma | 1 | 2019 | 2 | 0.170 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2019 | 16 | 0.170 |
Why?
|
| Preoperative Care | 1 | 2020 | 135 | 0.170 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 9 | 0.170 |
Why?
|
| Frailty | 1 | 2019 | 39 | 0.170 |
Why?
|
| Head | 1 | 2019 | 23 | 0.170 |
Why?
|
| Larynx | 1 | 2019 | 16 | 0.170 |
Why?
|
| Medical Illustration | 1 | 2019 | 20 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 177 | 0.170 |
Why?
|
| Lymph Nodes | 1 | 2019 | 71 | 0.170 |
Why?
|
| Pharynx | 1 | 2019 | 14 | 0.170 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 38 | 0.170 |
Why?
|
| Disease Management | 1 | 2020 | 122 | 0.170 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 38 | 0.160 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2018 | 3 | 0.160 |
Why?
|
| Reference Values | 1 | 2019 | 230 | 0.160 |
Why?
|
| Morphine | 1 | 2019 | 83 | 0.160 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 332 | 0.160 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1859 | 0.160 |
Why?
|
| Telemedicine | 1 | 2020 | 99 | 0.160 |
Why?
|
| Carcinoma | 1 | 2018 | 59 | 0.160 |
Why?
|
| Aging | 1 | 2007 | 1630 | 0.150 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 558 | 0.150 |
Why?
|
| Invasive Fungal Infections | 1 | 2017 | 4 | 0.140 |
Why?
|
| Frozen Sections | 1 | 2017 | 11 | 0.140 |
Why?
|
| Aspergillosis | 1 | 2017 | 11 | 0.140 |
Why?
|
| Mucormycosis | 1 | 2017 | 8 | 0.140 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 221 | 0.140 |
Why?
|
| Markov Chains | 1 | 2015 | 29 | 0.130 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 24 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 65 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 143 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 110 | 0.120 |
Why?
|
| Rhinitis | 1 | 2017 | 165 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 53 | 0.120 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 114 | 0.120 |
Why?
|
| Sinusitis | 1 | 2017 | 187 | 0.110 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 411 | 0.110 |
Why?
|
| Cricoid Cartilage | 1 | 2012 | 1 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 399 | 0.110 |
Why?
|
| Drainage | 2 | 2010 | 50 | 0.110 |
Why?
|
| Forearm | 1 | 2012 | 18 | 0.110 |
Why?
|
| Trachea | 1 | 2012 | 31 | 0.100 |
Why?
|
| Tongue Diseases | 1 | 2011 | 1 | 0.100 |
Why?
|
| Mouth Floor | 1 | 2011 | 2 | 0.100 |
Why?
|
| Organ Transplantation | 1 | 2012 | 37 | 0.100 |
Why?
|
| Laryngoscopy | 1 | 2011 | 21 | 0.100 |
Why?
|
| Patient Admission | 1 | 2011 | 30 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2012 | 67 | 0.100 |
Why?
|
| Otoscopy | 1 | 2010 | 1 | 0.090 |
Why?
|
| Remission, Spontaneous | 1 | 2010 | 10 | 0.090 |
Why?
|
| Hearing Tests | 1 | 2010 | 9 | 0.090 |
Why?
|
| Intubation, Intratracheal | 1 | 2011 | 78 | 0.090 |
Why?
|
| Mediastinal Diseases | 1 | 2010 | 4 | 0.090 |
Why?
|
| Hematoma | 1 | 2010 | 19 | 0.090 |
Why?
|
| Algorithms | 1 | 2011 | 400 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 2011 | 221 | 0.080 |
Why?
|
| Recurrence | 1 | 2010 | 354 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2011 | 312 | 0.080 |
Why?
|
| Lasers | 1 | 2007 | 16 | 0.080 |
Why?
|
| Embryo, Mammalian | 1 | 2007 | 30 | 0.080 |
Why?
|
| Pandemics | 2 | 2020 | 237 | 0.080 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2007 | 77 | 0.080 |
Why?
|
| Scattering, Radiation | 1 | 2007 | 40 | 0.080 |
Why?
|
| Fetus | 1 | 2007 | 56 | 0.080 |
Why?
|
| Hypertension | 1 | 2010 | 272 | 0.070 |
Why?
|
| Rabbits | 1 | 2007 | 283 | 0.070 |
Why?
|
| Printing, Three-Dimensional | 1 | 2023 | 5 | 0.060 |
Why?
|
| Immobilization | 1 | 2023 | 14 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 778 | 0.060 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 68 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 21 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 7 | 0.050 |
Why?
|
| Apoptosis | 1 | 2022 | 259 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2021 | 310 | 0.050 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 21 | 0.050 |
Why?
|
| Genomics | 1 | 2020 | 43 | 0.040 |
Why?
|
| Nasal Cavity | 1 | 2020 | 35 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 39 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 67 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 328 | 0.040 |
Why?
|
| Animals | 1 | 2007 | 4637 | 0.040 |
Why?
|
| Mass Screening | 1 | 2020 | 180 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 497 | 0.040 |
Why?
|
| Chicago | 1 | 2020 | 866 | 0.040 |
Why?
|
| Mucor | 1 | 2017 | 4 | 0.040 |
Why?
|
| Aspergillus | 1 | 2017 | 7 | 0.040 |
Why?
|
| Nasal Surgical Procedures | 1 | 2017 | 8 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 45 | 0.040 |
Why?
|
| Nose | 1 | 2017 | 35 | 0.030 |
Why?
|
| Acute Disease | 1 | 2017 | 225 | 0.030 |
Why?
|
| Endoscopy | 1 | 2017 | 181 | 0.030 |
Why?
|
| Decision Making | 1 | 2017 | 227 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 161 | 0.030 |
Why?
|
| Registries | 1 | 2015 | 191 | 0.030 |
Why?
|